Navigation Links
MedAvante Opens Moscow Office and Successfully Completes First Centralized Ratings Assessment
Date:5/6/2010

HAMILTON, N.J., May 6 /PRNewswire/ -- MedAvante, Inc., the leader in centralized evaluation of central nervous system (CNS) disorders, announced today the successful completion of the first study assessment using Centralized Ratings in their Moscow assessment center. MedAvante's Moscow headquarters is the first fully operational center for conducting Centralized Ratings located outside of the United States.

Remote centralized ratings are real-time assessments, either by telephone or videoconference, of subjects in global drug trials. Centralizing the assessors, the raters, results in a level of standardization and calibration that is not achievable with a decentralized group of study raters participating from unconnected investigative sites.

"MedAvante's methodology offers the possibility that an outcome measure can be administered in exactly the same way anywhere in the world ensuring improvements in data quality throughout a research study," said Valery Krasnov MD, PhD, Director, Moscow Research Institute of Psychiatry, President of the Russian Federation of Psychiatry and MedAvante Advisory Board co-chair. "As a physician and a scientist, I am dedicated to improving the way in which psychiatric trials are conducted and see Centralized Ratings as a way of doing so."

Centralized Ratings addresses trends in clinical trials such as decreasing drug effect and increasing placebo response, which have led to a high rate of expensive, yet uninformative, drug trials. "

MedAvante had always planned to expand the company's global presence. "While we had expanded our Continuous Quality Control (CQC) services to 25 countries throughout the world, we were waiting for the right opportunity to expand the more robust Centralized Ratings Platform outside of the United States. Sponsors saw the value in employing our methodology in Russia," said Paul Gilbert, CEO of MedAvante. "MedAvante provides sponsors with the assurance that regardless of where a trial is located, the same rigorous standards apply."

About MedAvante

MedAvante is the premier global provider of centralized expert psychiatric rating and monitoring services to the pharmaceutical, biotechnology and medical device industries. Centralizing raters makes it possible to continuously train and calibrate clinicians, which improves consistency and accuracy of the assessment of symptoms. The resulting level of standardization is not achievable with a larger group of decentralized raters participating from unconnected study sites. In addition, MedAvante raters are remote from the sites enrolling and treating the patients and thus can be more objective assessors of their symptoms. The company offers a range of services, including assessment of patients via high-quality real-time videoconferencing and quality control for trials via review of videotaped ratings.  MedAvante's research has shown that these improvements reduce trial failure rates, one of the most serious challenges facing the development of new psychiatric and neurologic treatments. MedAvante operates facilities in Hamilton, NJ; Madison, WI; and Moscow, Russia.


'/>"/>
SOURCE MedAvante, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ICON and MedAvante Sign Alliance Agreement
2. Elekta Opens a New Window into Human Brain Activity, Focuses on Brain Mets at 2010 AANS Meeting
3. Satellite Dialysis Opens New Center in Merced, CA
4. Convenient DR Walk-In Medical Center Opens in Chelsea, NYC
5. Medical Research Council Technologys Centre for Therapeutics Discovery Opens its First Call For Targets in an Effort to Develop Drugs in Areas of Serious Unmet Need
6. Millstone Medical Outsourcing Opens New, Advanced Clean Room to Expand Capacity for Sterile Packaging
7. Applied Technology Holdings, Inc. Opens New Headquarters in California
8. Roche Diagnostics Opens State-of-the-Art Training Center in California
9. American Scientific Resources Inc. Opens Shanghai Location
10. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
11. Diplomat Specialty Pharmacy Continues to Expand - Opens Location in Southern California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
Breaking Medicine News(10 mins):